Kevin Larkin was Appointed as Chief Executive Officer at TherOx

Date of management change: January 15, 2001 

What Happened?

Irvine, CA-based TherOx Appointed Kevin Larkin as Chief Executive Officer

 

About the Company

TherOx, Inc. (TherOx) is a private, venture-financed medical device company based in Irvine, California, dedicated to elevating the standard of care for treatment of heart attack patients. A heart attack is caused when an artery in the heart becomes blocked. Current treatment of heart attack is to reestablish blood flow in the blocked artery as quickly as possible. Typically, this is done with a combination of medication and a percutaneous coronary intervention (PCI) which may include the placement of a (intracoronary) stent. PCI successfully restores blood flow, but damage to the patient’s heart remains. Blood flow in the microvasculature downstream from the blockage is compromised, and critical heart muscle tissue is damaged – or infarcted – due to oxygen deprivation brought on by the heart attack. The intent of SuperSaturated Oxygen (SSO2) Therapy from TherOx is to salvage damaged heart tissue by placing a high concentration of oxygen (~760 – 1,000 mmHg, or 5 – 7 times normal levels) into the patient’s blood plasma and delivering it directly to the area impacted by the heart attack. SSO2 Therapy serves as a complement to PCI and stenting. Immediately following the interventional procedure, proprietary technology from TherOx mixes a pre-specified concentration of “SuperOxygenated” saline solution with the patient’s blood to produce SuperOxygenated blood. The SuperOxygenated blood is then delivered through a catheter to the oxygen deficient tissue. Company research has confirmed in clinical studies that SuperSaturated Oxygen Therapy has the potential to reverse ischemia and may resuscitate tissue that may otherwise die. SSO2 Therapy circulates the patient`s own blood via the existing arterial access site used for the stenting procedure. Thus, no new access site is required. The TherOx DownStream System and DownStream Cartridge bear the CE Mark but are not available for commercial distribution in the EU at this time.

 

About the Person

Kevin Larkin is the President, Chief Executive Officer and a director of TherOx, a medical device company, since May 2001. Has also been in the cardiovascular device field for 36 years, with broad business experience in both large and small companies. Prior to joining TherOx, was President and CEO of CardioVasc, a cardiovascular company directed from start-up through early clinical trials. Previously He served as Vice President of Sales and Marketing for Ventritex, where He established marketing, sales, education and customer service functions leading to first year sales of $105 million. Ventritex was acquired by St. Jude Medical. He had also held senior management positions in marketing, sales, and business development at Medtronic and Cordis Corporation (a Johnson & Johnson company).He also serve as a director for Cardica, a public cardiovascular company located in Redwood City, CA.

 

Info Source

Press Release

 
 

Other IT executives who recently changed jobs as well: Miller Glenn, Schuler Althea, Koutrakos Nicholas, Bristow Darcie, Lawson Tammy, Aron Julie, Fiehler Sharon, Varner Brandt, Dickey Kim, Compton Jennifer, Nieman Ray

You can find the full directory of IT executives here.

How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.